A Peek At Eli Lilly and Company (LLY)'s Strategy For Managing Digital Health Risks
7/15/2014 7:06:33 AM
When it comes to digital health, pharmaceutical companies tend to be slow and cautious, because of the onerous risks they face from the FDA should they improperly market a drug via the internet or mobile channels. But big pharma recognizes the need to innovate and stay on top of the times as well. That’s why the trend lately has been for large pharmaceutical companies to spin out a smaller group that doesn’t do drug marketing, to test the waters and set the company up for a more robust social media, web, and mobile presence. We’ve already seen that with Johnson and Johnson’s Janssen Healthcare Innovation and with Merck’s M2i2 enterprise.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by